The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH
Launched by UNIVERSITY OF ALBERTA · Nov 1, 2013
Trial Information
Current as of May 12, 2025
Completed
Keywords
ClinConnect Summary
Cardiovascular disease (CVD) is the leading cause of death worldwide accounting for nearly one third of the total deaths. The majority (90%) of the CVD cases are caused by modifiable risk factors. These factors include tobacco smoking, hypertension, hyperlipidemia, diabetes, physical inactivity, high fat diet and obesity.
In Canada CVD rates have decreased drastically over the last few decades, yet it is still one of the leading causes of death. It also carries a financial burden on the Canadian economy with a cost close to $ 21 billion every year divided between loss of productivity and h...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Adults (≥18 years of age) at high risk for cardiovascular events, including:
- • Patients with diabetes
- • Patients with chronic kidney disease \[eGFR \<60 ml/min/1.73m2 and/or (ACR \>= 30 mg/mmol or two consecutive ACR tests which are \>= 3 mg/mmol)\]
- • Patients with established atherosclerotic vascular disease including cerebrovascular disease (prior stroke or transient ischemic attack), cardiovascular disease (myocardial infarction, acute coronary syndrome, stable angina, or revascularization), or peripheral arterial disease (symptomatic and/or ankle brachial index \<0.9).
- • Primary prevention patients with multiple risk factors and Framingham risk score \>20%
- • In order to qualify for inclusion, all patients must have at least one uncontrolled risk factor (i.e., blood pressure, LDL-cholesterol, HbA1c, or current smoking)
- Exclusion Criteria:
- • Unwilling to participate/sign consent form
- • Unwilling or unable to participate in regular follow-up visits
- • Pregnancy
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Charlotte A Jones, MD, PhD
Principal Investigator
University of British Columbia - Southern Medical Program
Brenda Hemmelgarn, MD, PhD
Principal Investigator
Department of Medicine, University of Calgary
Ross T Tsuyuki, PharmD, MSc
Principal Investigator
Department of Medicine, University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials